Tango Therapeutics Inc (TNGX) concluded trading on Thursday at a closing price of $1.29, with 0.47 million shares of worth about $0.6 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -81.33% during that period and on April 17, 2025 the price saw a gain of about 0.78%. Currently the company’s common shares owned by public are about 107.73M shares, out of which, 59.12M shares are available for trading.
Stock saw a price change of -0.39% in past 5 days and over the past one month there was a price change of -25.22%. Year-to-date (YTD), TNGX shares are showing a performance of -58.25% which decreased to -82.45% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.11 but also hit the highest price of $12.02 during that period. The average intraday trading volume for Tango Therapeutics Inc shares is 728.28K. The stock is currently trading -8.51% below its 20-day simple moving average (SMA20), while that difference is down -31.87% for SMA50 and it goes to -75.74% lower than SMA200.
Tango Therapeutics Inc (NASDAQ: TNGX) currently have 107.73M outstanding shares and institutions hold larger chunk of about 55.97% of that.
The stock has a current market capitalization of $139.46M and its 3Y-monthly beta is at 1.03. It has posted earnings per share of -$1.20 in the same period. It has Quick Ratio of 6.98 while making debt-to-equity ratio of 0.18. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TNGX, volatility over the week remained 9.60% while standing at 11.67% over the month.
Stock’s fiscal year EPS is expected to drop by -17.02% while it is estimated to decrease by -1.56% in next year. EPS is likely to shrink at an annualized rate of -10.41% for next 5-years, compared to annual growth of 7.47% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on July 17, 2024 offering a Buy rating for the stock and assigned a target price of $19 to it. On February 12, 2024, Piper Sandler Initiated their recommendations, while on December 08, 2023, B. Riley Securities Initiated their ratings for the stock with a price target of $16. Stock get a Buy rating from H.C. Wainwright on October 20, 2022.
